Molecular Breast Imaging in Screening Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

June 1, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

June 1, 2019

Conditions
Breast Cancer
Interventions
DIAGNOSTIC_TEST

Molecular breast imaging

Molecular breast imaging will be performed at 5-10 minutes after intravenous injection of 15-20 millicurie (mCi) Tc-99m sestamibi. Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.

DIAGNOSTIC_TEST

Mammography

During the procedure, the breast is compressed using a dedicated mammography unit. Parallel-plate compression evens out the thickness of breast tissue to increase image quality by reducing the thickness of tissue that x-rays must penetrate, decreasing the amount of scattered radiation, reducing the required radiation dose, and holding the breast still (preventing motion blur). Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.

DIAGNOSTIC_TEST

Breast ultrasound

Ultrasound investigation of breast is performed by members of breast cancer team. If abnormality is found by the procedure, biopsy will not be performed directly.

Trial Locations (1)

204

TzuPei Su, Keelung

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT03082456 - Molecular Breast Imaging in Screening Breast Cancer | Biotech Hunter | Biotech Hunter